Crosstalk between Human IgG Isotypes and Murine Effector Cells

Development of human therapeutic Abs has led to reduced immunogenicity and optimal interactions with the human immune system in patients. Humanization had as a consequence that efficacy studies performed in mouse models, which represent a crucial step in preclinical development, are more difficult to interpret because of gaps in our knowledge of the activation of murine effector cells by human IgG (hIgG) remain. We therefore developed full sets of human and mouse isotype variants of human Abs targeting epidermal growth factor receptor and CD20 to explore the crosstalk with mouse FcγRs (mFcγRs) and murine effector cells. Analysis of mFcγR binding demonstrated that hIgG1 and hIgG3 bound to all four mFcγRs, with hIgG3 having the highest affinity. hIgG1 nevertheless was more potent than hIgG3 in inducing Ab-dependent cellular cytotoxicity (ADCC) and Ab-dependent cellular phagocytosis with mouse NK cells, mouse polymorphonuclear leukocytes, and mouse macrophages. hIgG4 bound to all mFcγRs except mFcγRIV and showed comparable interactions with murine effector cells to hIgG3. hIgG4 is thus active in the murine immune system, in contrast with its inert phenotype in the human system. hIgG2 bound to mFcγRIIb and mFcγRIII, and induced potent ADCC with mouse NK cells and mouse polymorphonuclear leukocytes. hIgG2 induced weak ADCC and, remarkably, was unable to induce Ab-dependent cellular phagocytosis with mouse macrophages. Finally, the isotypes were studied in s.c. and i.v. tumor xenograft models, which confirmed hIgG1 to be the most potent human isotype in mouse models. These data enhance our understanding of the crosstalk between hIgGs and murine effector cells, permitting a better interpretation of human Ab efficacy studies in mouse models.

[1]  C. Conner.  Therapy with Monoclonal Antibodies , 1984, Drug intelligence & clinical pharmacy.

[2]  M. Neuberger,et al.  Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies , 1987, The Journal of experimental medicine.

[3]  J. Ghrayeb,et al.  Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[4]  S L Morrison,et al.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. , 1989, Journal of immunology.

[5]  C. Anderson,et al.  Biology of Human Immunoglobulin G Fc Receptors , 1991, Journal of leukocyte biology.

[6]  J. Isaacs,et al.  Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. , 1992, Journal of immunology.

[7]  P. Parren,et al.  On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. , 1992, The Journal of clinical investigation.

[8]  P. Parren,et al.  Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. , 1992, Journal of immunology.

[9]  A. Lawson,et al.  A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. , 1993, Molecular immunology.

[10]  M. Glennie,et al.  HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. , 1996, Blood.

[11]  M. Madanat,et al.  Intrachain disulfide bond in the core hinge region of human IgG4 , 1997, Protein science : a publication of the Protein Society.

[12]  C. Kallenberg,et al.  Inflammation in autoimmunity: receptors for IgG revisited. , 2001, Trends in immunology.

[13]  R. Ober,et al.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.

[14]  R. Aalberse,et al.  The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. , 2001, Molecular immunology.

[15]  T. Valerius,et al.  Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity1 , 2002, The Journal of Immunology.

[16]  P. Parren,et al.  Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. , 2004, Blood.

[17]  P. Parren,et al.  Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy , 2004, The Journal of Immunology.

[18]  J. Ravetch,et al.  Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding , 2005, Science.

[19]  P. Bruhns,et al.  FcgammaRIV: a novel FcR with distinct IgG subclass specificity. , 2005, Immunity.

[20]  Robin Shattock,et al.  In Vitro and In Vivo: The Story of Nonoxynol 9 , 2005, Journal of acquired immune deficiency syndromes.

[21]  Shigeru Iida,et al.  IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. , 2005, Journal of immunological methods.

[22]  R. Herrmann,et al.  Overview of monoclonal antibodies in cancer therapy: present and promise. , 2005, Critical reviews in oncology/hematology.

[23]  P. Bruhns,et al.  FcγRIV : A novel FcR with distinct IgG subclass specificity , 2005 .

[24]  J. Leusen,et al.  The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. , 2006, Cancer research.

[25]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[26]  P. Parren,et al.  Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange , 2007, Science.

[27]  M. Pallardy,et al.  Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. , 2007, Critical reviews in oncology/hematology.

[28]  Tomoaki Nakagawa,et al.  Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. , 2008, Cancer research.

[29]  J. Ravetch,et al.  Fcγ receptors as regulators of immune responses , 2008, Nature Reviews Immunology.

[30]  J. Ravetch,et al.  Fcgamma receptors as regulators of immune responses. , 2008, Nature reviews. Immunology.

[31]  B. Nieswandt,et al.  Both FcγRIV and FcγRIII are essential receptors mediating type II and type III autoimmune responses via FcRγ‐LAT‐dependent generation of C5a , 2009, European journal of immunology.

[32]  P. Parren,et al.  Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage , 2009, The Journal of Immunology.

[33]  N. Van Rooijen,et al.  Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40 , 2008, British Journal of Cancer.

[34]  P. Bruhns,et al.  Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. , 2009, Blood.

[35]  K. Lewis,et al.  Comparison of the ability of wild type and stabilized human IgG(4) to undergo Fab arm exchange with endogenous IgG(4)in vitro and in vivo. , 2009, Molecular immunology.

[36]  J. Ravetch,et al.  FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo , 2010, Proceedings of the National Academy of Sciences.

[37]  I. Jónsdóttir,et al.  Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential , 2011, Nature communications.

[38]  P. Parren,et al.  Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition , 2011, The Journal of Immunology.

[39]  P. Parren,et al.  The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden , 2011, Haematologica.